UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 2, 2016
Versartis, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36361 |
|
26-4106690 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
4200 Bohannon Drive, Suite 250 Menlo Park, California |
|
94025 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code: (650) 963-8580
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01Regulation FD Disclosure.
Spokespersons of Versartis, Inc. (the “Company”) plan to present in oral sessions the information in the three slide decks attached hereto as Exhibits 99.1, 99.2 and 99.3 at the 17th International Congress of Endocrinology, being held August 31 to September 4, 2016, in Beijing, China.
The furnishing of the attached slide decks is not an admission as to the materiality of any information therein. The information contained in the slide decks is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibits 99.1, 99.2 and 99.3 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing
Item 8.01Other Events.
On September 2, 2016, the Company issued a press release titled “Versartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology.” A copy of the press release is attached hereto as Exhibit 99.4 and incorporated herein by reference.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|||
|
99.1 |
|
Company slide deck dated September 2016 titled “HbA1cover Two Years of Treatment with Somavaratan(VRS-317) in Children with Growth Hormone Deficiency (GHD) in the VISTA Study” |
||||
|
99.2 |
|
Company slide deck dated September 2016 titled “Somavaratan (VRS-317) Treatment for Pediatric Growth Hormone Deficiency (GHD): VISTA Study Results at 2.5 Years (NCT02068521) |
||||
|
99.3 |
|
Company slide deck dated September 2016 titled “Treatment Adherence with Weekly, Twice-Monthly and Monthly Dosing of Somavaratan (VRS-317), a Long-Acting Growth Hormone Treatment for Children with Growth Hormone Deficiency (GHD), After 24 Months of At-Home Dosing in the VISTA Study” |
||||
|
99.4 |
|
Press release dated September 2, 2016, titled “Versartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology” |
||||
|
|
|
|
||||
|
|
|
Press Release, issued by Versartis, Inc. on February 18, 2016. |
||||
|
|
|
Press Release, issued by Versartis, Inc. on February 18, 2016. |
||||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: September 2, 2016 |
|
VERSARTIS, INC. (Registrant) |
||
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Joshua T. Brum |
|
|
|
|
|
Joshua T. Brumm |
|
|
|
|
|
Chief Financial Officer |
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Company slide deck dated September 2016 titled “HbA1cover Two Years of Treatment with Somavaratan(VRS-317) in Children with Growth Hormone Deficiency (GHD) in the VISTA Study” |
|
|
99.2 |
|
Company slide deck dated September 2016 titled “Somavaratan (VRS-317) Treatment for Pediatric Growth Hormone Deficiency (GHD): VISTA Study Results at 2.5 Years (NCT02068521) |
|
|
99.3 |
|
Company slide deck dated September 2016 titled “Treatment Adherence with Weekly, Twice-Monthly and Monthly Dosing of Somavaratan (VRS-317), a Long-Acting Growth Hormone Treatment for Children with Growth Hormone Deficiency (GHD), After 24 Months of At-Home Dosing in the VISTA Study” |
|
|
99.4 |
|
Press release dated September 2, 2016, titled “Versartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology” |
|
|
|
|
|
|
|
|
|
|
|